BridgeMD
New treatment option for APL
Official title Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia
ClinicalTrials.gov ID: NCT05881265
What this study is testing
What is Chidamide+venetoclax?
Chidamide+venetoclax is an investigational medicine, being studied as a potential treatment for apl.
Also referred to as Chi-VEN.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Based on the current treatment with retinoic acid (ATRA) and arsenic (As), most patients with APL achieved long-term survival. There are few patients relapsed and became refractory to the RA and As treatment.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 16 to 70
You may be able to join if
- Patients with PML-RARα+ APL
- Patients in non-remission status after treatment of RA combined with As
- Patients with life expectance \>=3 months
- Inform consent provided
You likely can't join if
- Patients with incontrollable infection
- Patients with life-expectancy less than 2 months
- Patients with abnormal liver (\>3XN) and renal function (\>3XN）
The study team makes the final eligibility decision.
Where it's taking place
- Huai'an, Jiangsu, China
- Nanchang, Jiangxi, China
- Shanghai, Shanghai Municipality, China
- Guangzhou, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 16 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Huai'an, Jiangsu, China; Nanchang, Jiangxi, China; Shanghai, Shanghai Municipality, China; Guangzhou, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.